ESMO Targeted Anticancer Therapies Congress 2022

Search results (9)

Breast Cancer

7 Mar 2022

The genomic, immunological and clinical characterisation of breast cancer – a work in progress

Read more

Lung and other thoracic tumours

7 Mar 2022

Combining WEE1 inhibition with PD-L1 blockade shows promise in SCLC models

Read more

Anticancer agents & Biologic therapy

7 Mar 2022

Will finding the optimal dosing regimen be the key to unlocking the potential of ATR inhibitors?

Read more

Anticancer agents & Biologic therapy

7 Mar 2022

Lesley Seymour receives the TAT Honorary Award 2022

Read more

Lung and other thoracic tumours

7 Mar 2022

Poziotinib does not meet the expectations to target insertion mutations in HER2 exon 20 in NSCLC

Read more

Cancer in Special Situations / Population

7 Mar 2022

COVID-19 vaccination is key to restoring early-phase anticancer drug development

Vaccination among cancer patients should not affect their participation in clinical trials and levels of acceptance of the vaccine are high 

By Emiliano Calvo

Read more

Lung and other thoracic tumours

7 Mar 2022

Sitravatinib shows signals of enhancing checkpoint inhibitor efficacy in NSCLC progressing on immunotherapy

Read more

Anticancer agents & Biologic therapy

7 Mar 2022

Exploring targeted degradation of KRAS G12C with PROTACs

Read more

Anticancer agents & Biologic therapy

7 Mar 2022

Will antibody–drug conjugates be a replacement for chemotherapy in the future?

Over the last decade, much progress has been made in developing a range of antibody–drug conjugates to treat breast cancer, with the construction of bespoke agents for individual patients and exciting prospect for the future

By Aditya Bardia

Read more